Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Mauro Gacci, University of Florence, Italy
  • Karl-Erik Andersson
  • Christopher Chapple, Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, United Kingdom
  • Mario Maggi, University of Florence, Italy
  • Vincenzo Mirone, Federico II University of Naples, Italy
  • Matthias Oelke, Department of Urology, Hannover Medical School, Hannover, Germany, Germany
  • Hartmut Porst, Private Institute for Urology,Andrology and Sexual Medicine, Hamburg, Germany, Germany
  • Claus Roehrborn, Department of Urology, UT Southwestern Medical Center at Dallas, TX, USA, United States
  • Christian G Stief, Department of Urology, Ludwig-Maximilians-Universität München, Germany, Germany
  • François Giuliano, Inserm U1179 Versailes - Saint Quentin University Montigny-le-Bretonneux, R. Poincaré Hospital - Assistance Publique-Hôpitaux de Paris, Garches, France, France
Original languageEnglish
JournalEuropean Urology
Pages (from-to)124-133
Number of pages10
Publication statusPublished - 2016

See relations at Aarhus University Citationformats

ID: 110746527